These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

462 related articles for article (PubMed ID: 31703717)

  • 21. Frailty and Risk of Serious Infections in Patients With Rheumatoid Arthritis Treated With Biologic or Targeted-Synthetic Disease-Modifying Antirheumatic Drugs.
    Singh N; Gold LS; Lee J; Wysham KD; Andrews JS; Makris UE; England BR; George MD; Baker JF; Jarvik J; Heagerty PJ; Singh S
    Arthritis Care Res (Hoboken); 2024 May; 76(5):627-635. PubMed ID: 38116680
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Real-world patient characteristics and use of disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: a cross-national study.
    Ingrasciotta Y; Jin Y; Foti SS; Landon JE; Tari M; Mattace-Raso F; Kim SC; Trifirò G
    Clin Rheumatol; 2023 Apr; 42(4):1047-1059. PubMed ID: 36534353
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analysis of efficacy and safety of abatacept for rheumatoid arthritis: systematic review and meta-analysis.
    Mohamed Ahamada M; Wu X
    Clin Exp Rheumatol; 2023 Sep; 41(9):1882-1900. PubMed ID: 36912326
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice: A Nationwide Cohort Study From Sweden.
    Wadström H; Frisell T; Askling J;
    JAMA Intern Med; 2017 Nov; 177(11):1605-1612. PubMed ID: 28975211
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risk of tuberculosis, serious infection and lymphoma with disease-modifying biologic drugs in rheumatoid arthritis patients in Taiwan.
    Chiu YM; Lang HC; Lin HY; Yang MT; Fang CH; Yang YW; Schabert VF; Tang B
    Int J Rheum Dis; 2014 Dec; 17 Suppl 3():9-19. PubMed ID: 25496045
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictive risk factors of serious infections in patients with rheumatoid arthritis treated with abatacept in common practice: results from the Orencia and Rheumatoid Arthritis (ORA) registry.
    Salmon JH; Gottenberg JE; Ravaud P; Cantagrel A; Combe B; Flipo RM; Schaeverbeke T; Houvenagel E; Gaudin P; Loeuille D; Rist S; Dougados M; Sibilia J; Le Loët X; Meyer O; Solau-Gervais E; Marcelli C; Bardin T; Pane I; Baron G; Perrodeau E; Mariette X;
    Ann Rheum Dis; 2016 Jun; 75(6):1108-13. PubMed ID: 26048170
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Abatacept initiation in rheumatoid arthritis and the risk of serious infection: A population-based cohort study.
    Montastruc F; Renoux C; Hudson M; Dell'Aniello S; Simon TA; Suissa S
    Semin Arthritis Rheum; 2019 Jun; 48(6):1053-1058. PubMed ID: 30772001
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of infection-related hospitalization risk and costs in tumor necrosis factor inhibitor-experienced patients with rheumatoid arthritis (RA) treated with abatacept or other targeted disease-modifying anti-rheumatic drugs (tDMARDs).
    Paul D; Patil D; McDonald L; Patel V; Lobo F
    J Med Econ; 2020 Sep; 23(9):1025-1031. PubMed ID: 32427547
    [No Abstract]   [Full Text] [Related]  

  • 29. Risk of hospitalized bacterial infections associated with biologic treatment among US veterans with rheumatoid arthritis.
    Curtis JR; Yang S; Patkar NM; Chen L; Singh JA; Cannon GW; Mikuls TR; Delzell E; Saag KG; Safford MM; DuVall S; Alexander K; Napalkov P; Winthrop KL; Burton MJ; Kamauu A; Baddley JW
    Arthritis Care Res (Hoboken); 2014 Jul; 66(7):990-7. PubMed ID: 24470378
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Abatacept in rheumatoid arthritis and the risk of cancer: a world observational post-marketing study.
    de Germay S; Bagheri H; Despas F; Rousseau V; Montastruc F
    Rheumatology (Oxford); 2020 Sep; 59(9):2360-2367. PubMed ID: 31880308
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis.
    Ramiro S; Gaujoux-Viala C; Nam JL; Smolen JS; Buch M; Gossec L; van der Heijde D; Winthrop K; Landewé R
    Ann Rheum Dis; 2014 Mar; 73(3):529-35. PubMed ID: 24401994
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative risk of osteoporotic fracture among patients with rheumatoid arthritis receiving TNF inhibitors versus other biologics: a cohort study.
    Shin A; Park EH; Dong YH; Ha YJ; Lee YJ; Lee EB; Song YW; Kang EH
    Osteoporos Int; 2020 Nov; 31(11):2131-2139. PubMed ID: 32514765
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritis.
    Zhang J; Xie F; Yun H; Chen L; Muntner P; Levitan EB; Safford MM; Kent ST; Osterman MT; Lewis JD; Saag K; Singh JA; Curtis JR
    Ann Rheum Dis; 2016 Oct; 75(10):1813-8. PubMed ID: 26792814
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Factors associated with mental illness in patients with rheumatoid arthritis initiating b/ts DMARDs: A population-based study.
    Chen HH; Wu PY; Lin CH; Wu CL; Chao WC
    Int J Rheum Dis; 2024 Jan; 27(1):e14992. PubMed ID: 38061767
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Four-year follow-up of atherogenicity in rheumatoid arthritis patients: from the nationwide Korean College of Rheumatology Biologics Registry.
    Min HK; Kim HR; Lee SH; Shin K; Kim HA; Park SH; Kwok SK
    Clin Rheumatol; 2021 Aug; 40(8):3105-3113. PubMed ID: 33576925
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Infections requiring hospitalization in the abatacept clinical development program: an epidemiological assessment.
    Simon TA; Askling J; Lacaille D; Franklin J; Wolfe F; Covucci A; Suissa S; Hochberg MC;
    Arthritis Res Ther; 2010; 12(2):R67. PubMed ID: 20398273
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serious infection across biologic-treated patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.
    Rutherford AI; Subesinghe S; Hyrich KL; Galloway JB
    Ann Rheum Dis; 2018 Jun; 77(6):905-910. PubMed ID: 29592917
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk of Biologics and Glucocorticoids in Patients With Rheumatoid Arthritis Undergoing Arthroplasty: A Cohort Study.
    George MD; Baker JF; Winthrop K; Alemao E; Chen L; Connolly S; Hsu JY; Simon TA; Wu Q; Xie F; Yang S; Curtis JR
    Ann Intern Med; 2019 Jun; 170(12):825-836. PubMed ID: 31108503
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Overall infection risk in rheumatoid arthritis during treatment with abatacept, rituximab and tocilizumab; an observational cohort study.
    Grøn KL; Glintborg B; Nørgaard M; Mehnert F; Østergaard M; Dreyer L; Krogh NS; Hetland ML
    Rheumatology (Oxford); 2020 Aug; 59(8):1949-1956. PubMed ID: 31764977
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Incidence of dementia in patients with rheumatoid arthritis and association with disease modifying anti-rheumatic drugs - Analysis of a national claims database.
    Sattui SE; Navarro-Millan I; Xie F; Rajan M; Yun H; Curtis JR
    Semin Arthritis Rheum; 2022 Dec; 57():152083. PubMed ID: 36155968
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.